Progress of anterior gradient protein 2 and anterior gradient protein 3 in the diagnosis and treatment of ovarian cancer
10.3760/cma.j.cn115355-20220522-00319
- VernacularTitle:前梯度蛋白2与前梯度蛋白3在卵巢癌诊治中的研究进展
- Author:
Xiaolei ZHANG
1
;
Suwei ZHANG
;
Yanli FENG
Author Information
1. 济宁医学院临床医学院，济宁 272013
- Keywords:
Anterior gradient protein 2;
Anterior gradient protein 3;
Ovarian neoplasms;
Diagnosis;
Prognosis;
Treatment
- From:
Cancer Research and Clinic
2023;35(1):77-80
- CountryChina
- Language:Chinese
-
Abstract:
Ovarian cancer ranks the third among gynecological malignancies, while its mortality rate is the highest. Even though recent treatment progress has been made after using PARP inhibitors, the prognosis is still poor. Anterior gradient protein 2 (AGR2) may be a marker for early diagnosis of ovarian cancer, and the expression of AGR2 suggests that the prognosis of ovarian cancer is better. However, Anterior gradient protein 3 (AGR3) could be used to differentiate high-grade and low-grade ovarian cancer, but its influence on prognosis is still controversial. AGR2 and AGR3 may be therapeutic targets for ovarian cancer. This article introduces the research progress of AGR2 and AGR3 in the diagnosis and treatment of ovarian cancer.
